RARE Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Ultragenyx Pharmaceutical Inc (RARE) is not a strong buy for a beginner investor with a long-term strategy at this time. The stock's technical indicators are bearish, insider selling is high, and while there are some positive developments in clinical trials, the company's financial performance and analyst sentiment suggest caution. Given the lack of strong proprietary trading signals and the mixed sentiment, holding off on investing is advisable until clearer positive catalysts emerge.
The stock's technical indicators are bearish. The MACD is positive but contracting, RSI is neutral at 40.375, and moving averages indicate a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading near its support level of 21.01, with resistance at 23.187. This suggests limited upward momentum in the short term.
Ultragenyx's Phase 3 study of DTX301 met its primary goal, showing an 18% reduction in plasma ammonia levels with a favorable safety profile. Additionally, the company's restructuring efforts aim to reduce costs and pave the way to profitability by 2027.
Insider selling has increased significantly by 3116.78% over the last month, indicating a lack of confidence from insiders. Analysts have significantly lowered price targets across the board, citing regulatory risks, uneven revenue patterns, and reduced revenue growth expectations. The company is also facing a class action lawsuit related to undisclosed material information.
In Q4 2025, revenue increased by 25.72% YoY to $207.3M, driven by Crysvita and Dojolvi. However, net income dropped by 3.62% YoY to -$128.6M, EPS fell by 7.19% YoY to -1.29, and gross margin declined by 4.36% YoY to 85.84%. The financials indicate growth in revenue but ongoing challenges with profitability.
Analysts have lowered price targets significantly, with JPMorgan reducing its target from $120 to $74 and other firms following suit. Despite this, many analysts maintain Buy or Overweight ratings, citing potential long-term catalysts such as GTX-102 and gene therapy programs. However, the near-term outlook remains cautious due to regulatory risks and uneven revenue patterns.
